<DOC>
	<DOC>NCT00159770</DOC>
	<brief_summary>Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice</brief_summary>
	<brief_title>Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Inpatients or outpatients with schizophrenia, schizoaffective and schizophreniform disorders (DSMIV). Patients without adequate current treatment (i.e. intolerance to their current treatment or lack of efficacy of current treatment) based on clinical judgement of the investigator A history of intolerance to ziprasidone, olanzapine, risperidone or quetiapine or any of its ingredients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>